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Summary
Background Patients with muscle-invasive urothelial carcinoma of the bladder have poor survival after cystectomy. 
The EORTC 30994 trial aimed to compare immediate versus deferred cisplatin-based combination chemotherapy 
after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder. 
Methods This intergroup, open-label, randomised, phase 3 trial recruited patients from hospitals across Europe and 
Canada. Eligible patients had histologically proven urothelial carcinoma of the bladder, pT3–pT4 disease or node positive 
(pN1–3) M0 disease after radical cystectomy and bilateral lymphadenectomy, with no evidence of any microscopic residual 
disease. Within 90 days of cystectomy, patients were centrally randomly assigned (1:1) by minimisation to either immediate 
adjuvant chemotherapy (four cycles of gemcitabine plus cisplatin, high-dose methotrexate, vinblastine, doxorubicin, and 
cisplatin [high-dose MVAC], or MVAC) or six cycles of deferred chemotherapy at relapse, with stratifi cation for institution, 
pT category, and lymph node status according to the number of nodes dissected. Neither patients nor investigators were 
masked. Overall survival was the primary endpoint; all analyses were by intention to treat. The trial was closed after 
recruitment of 284 of the planned 660 patients. This trial is registered with ClinicalTrials.gov, number NCT00028756.
Findings From April 29, 2002, to Aug 14, 2008, 284 patients were randomly assigned (141 to immediate treatment and 
143 to deferred treatment), and followed up until the data cutoff  of Aug 21, 2013. After a median follow-up of 7·0 years 
(IQR 5·2–8·7), 66 (47%) of 141 patients in the immediate treatment group had died compared with 82 (57%) of 143 in 
the deferred treatment group. No signifi cant improvement in overall survival was noted with immediate treatment 
when compared with deferred treatment (adjusted HR 0·78, 95% CI 0·56–1·08; p=0·13). Immediate treatment 
signifi cantly prolonged progression-free survival compared with deferred treatment (HR 0·54, 95% CI 0·4–0·73, 
p<0·0001), with 5-year progression-free survival of 47·6% (95% CI 38·8–55·9) in the immediate treatment group and 
31·8% (24·2–39·6) in the deferred treatment group. Grade 3–4 myelosuppression was reported in 33 (26%) of 
128 patients who received treatment in the immediate chemotherapy group versus 24 (35%) of 68 patients who received 
treatment in the deferred chemotherapy group, neutropenia occurred in 49 (38%) versus 36 (53%) patients, respectively, 
and thrombocytopenia in 36 (28%) versus 26 (38%). Two patients died due to toxicity, one in each group. 
Interpretation Our data did not show a signifi cant improvement in overall survival with immediate versus deferred 
chemotherapy after radical cystectomy and bilateral lymphadenectomy for patients with muscle-invasive urothelial 
carcinoma. However, the trial is limited in power, and it is possible that some subgroups of patients might still benefi t 
from immediate chemotherapy. An updated individual patient data meta-analysis and biomarker research are needed 
to further elucidate the potential for survival benefi t in subgroups of patients.
Funding Lilly, Canadian Cancer Society Research.
Introduction 
Radical cystectomy is the standard, potentially curative, 
surgical treatment for patients with muscle-invasive 
bladder cancer. However, 5-year overall survival for 
patients with pT3–pT4 pN– and pN+ M0 bladder cancer 
after radical cystectomy is about 50%. Overall survival 
ranges at best from 32% in patients with lymph node 
involvement to 75% in those without lymph node 
involvement and depends on optimal removal of 
adequate numbers of pelvic lymph nodes.1 Recurrence is 
thought to be due mainly to systemic disease occult at the 
time of cystectomy. This problem can be addressed by 
use of either neoadjuvant or adjuvant systemic 
chemotherapy. Evidence for effi  cacy of neoadjuvant 
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chemotherapy for patients at high risk for recurrence is 
greater than for adjuvant chemotherapy.2 Nonetheless, in 
most countries immediate cystectomy is preferred.2 
Adjuvant chemotherapy after local treatment has led to 
increases in survival in patients with many diff erent 
types of solid tumours.3 The main advantage is that 
cystectomy is done immediately, with no delay in 
defi nitive treatment, and that the pathological pT/pN 
categories can be assessed. Stage and lymph node status 
are known prognostic factors for progression and 
survival.4 High-risk patients who might benefi t the most 
could then be selected to receive adjuvant chemotherapy. 
Combination cisplatin-containing chemotherapy 
regimens for metastatic bladder can produce a response 
in up to 70% of patients.2 Three or four cycles of adjuvant 
chemotherapy after cystectomy aim to delay recurrence 
and extend survival in patients with muscle invasive 
bladder cancer or those with regional lymph node 
metastases.
Several randomised trials have attempted to address 
this issue.5 Skinner and colleagues6 were the fi rst to 
report purportedly positive results with adjuvant 
combination chemotherapy, followed by Stockle and 
colleagues7 and Freiha and colleagues.8 All these trials of 
combination chemotherapy showed a disease-free 
survival diff erence in favour of adjuvant chemotherapy. 
Unfortunately, no conclusions for clinical practice could 
be drawn from these trials, which had small sample sizes 
and confusing analyses and terminology. Additionally, 
treatment was not standardised after recurrence. The 
analysis of overall survival, probably the most important 
endpoint, was either not done or was inconclusive.5
Results of an individual patient-based meta-analysis 
comparing immediate adjuvant chemotherapy to no or 
delayed adjuvant chemotherapy suggested a decrease in 
the relative risk of death with adjuvant cisplatin-based 
chemotherapy (hazard ratio [HR] 0·75, 95% CI 
0·60–0·96), which represents a 9% (95% CI 1–16) 
absolute improvement in 3-year survival (p=0·19). 
Nonetheless, the CIs were very wide since the survival 
analysis was based on only 491 patients and 283 deaths.9 
Because of the limited power of the meta-analysis and 
the methodological problems encountered in the studies 
that were included, the investigators concluded that 
evidence on which to reliably base treatment decisions 
concerning adjuvant chemotherapy in bladder cancer 
was insuffi  cient.
Since then, two other contemporary randomised trials 
have attempted to address the question of adjuvant 
chemotherapy in advanced urothelial carcinoma.10,11 Both 
had diffi  culties with enrolment and premature closure. 
In an Italian multicentre trial,10 194 patients with pT2G3, 
pT3–4, N0–2 were randomly assigned between two 
diff erent schedules of gemcitabine plus cisplatin or 
observation.10 No diff erence in overall survival between 
the two groups was reported (HR 1·29, 95% CI 
0·84–1·99; p=0·24). In a unpublished Spanish trial 
presented at the 2010 American Society of Clinical 
Oncology annual meeting,11 142 patients were randomly 
assigned to paclitaxel plus gemcitabine plus cisplatin 
therapy or observation. Adjuvant chemotherapy with 
paclitaxel plus gemcitabine plus cisplatin resulted in 
improved outcomes, including overall survival. In the 
intention-to-treat analysis, the adjusted HR for benefi t 
was 0·38 (95% CI 0·22–0·65; p<0·0009). The fi nal 
sample size of the study limits the robustness of these 
conclusions.11
Leow and colleagues12 have subsequently done a meta-
analysis of the use of adjuvant chemotherapy in this 
setting, including 945 patients from nine randomised 
trials. The results suggest an overall survival and disease-
free survival benefi t with adjuvant cisplatin-based 
chemotherapy after radical cystectomy. Adding to existing 
evidence, we now report the fi nal analyses of the EORTC 
study 30994, which was designed to establish whether 
immediate adjuvant chemotherapy after cystectomy 
could provide a survival benefi t. 
Methods 
Study design and patients 
In this intergroup, open-label, randomised, phase 3 trial, 
patients were recruited from hospitals across 12 European 
countries and Canada. Eligible patients had histologically 
proven urothelial carcinoma of the bladder, pT3–pT4 
disease or node positive (pN1–3) M0 disease (UICC 1997),13 
or both, after radical cystectomy and bilateral lympha-
denectomy. The dissection of a minimum of 15 lymph 
nodes was recommended. No evidence of any microscopic 
residual disease (R0) was mandatory. Adequate surgical 
resection was defi ned by whether or not 15 or more lymph 
nodes were resected and no microscopic residual disease 
was left in place. No central pathology review took place. 
Chemotherapy was to be started within 90 days of surgery. 
No age limits were applied, but patients had to have a 
good per formances status (WHO 0 or 1), adequate 
heamatological function (white blood cell count 
≥3·5 × 10⁹ cells per L and platelet count ≥120 × 10⁹ cells 
per L), adequate renal function (glomerular fi ltration rate 
≥60 mL/min), and normal auditory and cardiac function. 
Patients with previous systemic chemotherapy or radiation 
to the bladder and patients regarded as unfi t for cisplatin-
containing combination chemotherapy or with grade 2 or 
worse peripheral neuropathy were ineligible. 
All patients provided written informed consent. The 
institutional review board or independent ethics 
committee at each site approved the protocol. The study 
was done according to national or local regulations, the 
Declaration of Helsinki, and the International Conference 
on Harmonisation Guidelines for Good Clinical Practice. 
Randomisation and masking 
Randomisation was done centrally at the EORTC 
headquarters in Brussels, Belgium. Patients were 
allocated (1:1) to either immediate or deferred systemic 
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chemotherapy using a minimisation technique14 with the 
following stratifi cation factors: institution, pT category 
(pTa–1–2 vs pT3 vs pT4ab) and lymph node status 
according to the number of nodes dissected (pN+ vs pN– 
with <15 nodes dissected vs pN– with ≥15 nodes 
dissected). Neither patients, those administering the 
interventions, nor those assessing the outcomes were 
masked in this study.
Procedures
Each participating centre prospectively chose one of three 
diff erent regimens to be given in both the immediate and 
deferred groups of the study: methotrexate, vinblastine, 
doxorubicin, and cisplatin (MVAC);15 high-dose MVAC 
given every 2 weeks (with granulocyte colony-stimulating 
factor);16 or gemcitabine plus cisplatin.17 Four cycles were 
administered to patients receiving immediate chemo-
therapy with no further treatment until relapse. Patients 
assigned to the deferred group had no treatment until 
relapse. Treatment upon relapse was recommended to 
consist of six cycles of the regimen chosen by the centre. 
Chemotherapy was to be defi nitively stopped if treatment 
was delayed for more than 4 consecutive weeks because of 
toxicity. Prescribed doses and dose modifi cations are 
described in the appendix. 
Patients underwent the same imaging (whole body CT 
scan or abdominal MRI and radiograph of the thorax or 
CT of the chest) of lesions at baseline and during follow-
up visits. During treatment only physical examination, 
haematology, and biochemistry were done. All patients 
had their fi rst post-surgery clinical and imaging 
assessments before randomisation, which served as a 
baseline reference. Further clinical and imaging 
assessments were scheduled for the immediate group 
every 3 months during the fi rst year after treatment, 
every 6 months during years 2–5, and yearly thereafter. 
Patients in the deferred group had visits at essentially 
the same schedule starting from baseline, with scans 
every 3 months, but on progression, treatment was given 
and the more intense visit schedule was restarted as in 
the immediate group. 
Clinical progression was diagnosed by clinical or 
radiological examinations that were mandated annually 
or upon suspicion of relapse. Laboratory values were 
obtained at regular intervals. Adverse events were 
recorded if serious or leading to permanent treatment 
discontinuation. Adverse events were scored by Common 
Terminology Criteria for Adverse Events (CTCAE) 
version 2.0. The CTCAE grades were calculated with 
reference to the following lower normal limits: leucocytes 
4 × 10⁹ cells per L; neutrophils or granulocytes 2 × 10⁹ cells 
per L; platelets 100 × 10⁹ cells per L; haemoglobin 12 g/dL; 
and the following upper normal limits: bilirubin 
18 μmol/L; alkaline phosphatase 120 units/L; alanine 
amino transferase 35 units per L; aspartate amino-
transferase 35 units per L; serum creatinine 110 μmol/L. 
Quality of life was not assessed. 
Outcomes
The primary endpoint was overall survival and was 
assessed from randomisation to the date of death from 
any cause. The only secondary endpoint, progression-
free survival, was calculated from randomisation to fi rst 
local, locoregional, or distant progression, or death from 
any cause.  Patients without an event were censored at 
their last visit. We also report an exploratory analysis of 
bladder cancer mortality, defi ned as survival until death 
due to bladder cancer, with deaths of unknown or other 
causes taken as competing risks. 
Statistical analysis
The trial was originally designed to detect an increase in 
5-year overall survival from 35% in the deferred 
chemotherapy (control) group to 42% in the immediate 
chemotherapy group (HR 0·826) with two-sided 
signifi cance level of 0·05 and 80% power (864 deaths 
needed). 1344 patients were to be entered over 5·4 years 
with fi nal results anticipated 3 years after the last patient 
had been entered. 
Because it was noted that a high proportion of patients 
with lymph node involvement had been enrolled, the 
statistical objectives were revised in July, 2005, in a 
substantial amendment that reset the targeted diff erence 
to a HR of 0·76, decreasing the target sample size to 
660 patients, and allowed patients with incidental 
prostate cancer to be included. The study was closed to 
patient entry in August, 2008, because of poor accrual 
after 284 of the planned 660 patients had been included. 
Figure 1: Study fl owchart
MVAC=methotrexate, vinblastine, doxorubicin, and cisplatin.
143 assigned to deferred chemotherapy
284 randomly assigned
141 assigned to immediate chemotherapy
67 received treatment (57 gemcitabine plus 
      cisplatin; 9 high-dose MVAC; 1 MVAC)
      64 received deferred chemotherapy
             64 had progressive disease
      3 received immediate chemotherapy 
      2 did not have progressive disease
      1 had progressive disease
76 did not receive treatment
 53 did not have progressive disease
  13 dead
  40 alive
 23 had progressive disease
  2 refusal
  6 unfit
  5 other treatment
  9 died shortly after disease progression
  1 no data
128 received treatment (immediate chemotherapy)
 108 gemcitabine plus cisplatin
 19 high-dose MVAC 
 1 MVAC
   13 did not receive treatment
 4 refusal
 3 unfit
 6 no data
143 included in analysis141 included in analysis
See Online for appendix
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On the basis of advice from the independent data 
monitoring committee, follow-up was to continue for an 
additional 5 years, at which time 143 deaths were 
expected. This allowed testing for a 15% improvement 
in 5-year survival from 50% to 65%, HR 0·62, at an 
overall two-sided signifi cance level of 0·05 with 80% 
power. A fi rst interim analysis tested for superiority in 
June, 2007, and a second tested for futility in June, 2011; 
both recommended continuation of the trial (appendix).
We estimated overall survival and progression-free 
survival by the Kaplan-Meier method.18 We compared 
treatments in all patients using the Cox proportional 
hazards regression model,19 stratifi ed for the participating 
collaborative group (EORTC vs non-EORTC) and 
adjusted for the pT category (<pT3 vs pT3–4) and pN 
status (pN– vs pN+). We estimated cumulative incidence 
of bladder cancer mortality and mortality due to other 
causes by cumulative incidence and compared them by 
Fine-and-Gray models20 with the same adjustments as for 
the Cox model. To maintain an overall two-sided 
signifi cance level of 0·05, we did the fi nal analysis of the 
primary endpoint at the nominal two-sided signifi cance 
level of 0·0491 (adjusting for the interim analysis). 
Analyses were by intention to treat in all randomly 
assigned patients.
We did exploratory analyses of the heterogeneity of 
treatment eff ect across groups defi ned by age, sex, pT, 
pN, and pTN categories by using interaction tests in the 
Cox model, and presented them graphically using forest 
plots. We presented results in subgroups only if we noted 
statistically signifi cant heterogeneity (p<0·05).
We did all analyses using SAS version 9.4. This trial is 
registered with ClincalTrials.gov, number NCT00028756. 
Role of the funding source
The funder (Lilly) had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The sponsor of the trial was the EORTC. The 
corresponding author had full access to all study data and 
the fi nal responsibility for the decision to submit for 
publication. Trial design, conduct, and analysis were 
done at the EORTC, independent of all funding bodies.
Results
From April 29, 2002, to Aug 14, 2008, when the trial was 
prematurely closed to patient entry, 284 patients from 
63 sites (appendix) in 12 countries in Europe 
(272 patients) and Canada (12 patients) were randomly 
assigned after cystectomy: 141 were assigned to 
immediate chemotherapy and 143 to deferred 
chemotherapy (fi gure 1). Follow-up continued for 
5 years after closure, until August, 2013. Median follow-
up of all patients was 7·0 years (IQR 5·2–8·7; 7·0 years 
[5·1–8·7] in the immediate chemotherapy group vs 
7·2 years [5·6–8·7] in the deferred chemotherapy 
group) and maximum follow-up was 10·6 years 
(10·4 years vs 10·6 years, respectively). The median 
follow-up for alive patients was 6·1 years (IQR 4·5–8·5), 
ranging from no follow-up data (in nine patients) to 
10·6 years (6·1 years [4·5–8·5] in the immediate 
Immediate chemotherapy 
(n=141)
Deferred chemotherapy 
(n=143)
Age (years)
≤60 67 (48%) 70 (49 %)
>60 74 (52%) 73 (51%)
Median (IQR) 61 (55–67) 61 (55–67)
Range 37–76 35–82 
Sex 
Male 112 (79%) 114 (80%)
Female 27 (19%) 27 (19%)
Missing 2 (1%) 2 (1%)
WHO performance status
0 97 (69%) 101 (71%)
1 44 (31%) 42 (29%)
Time from cystectomy to randomisation (days)
≤30 22 (16%) 15 (10%)
31–60 43 (30%) 47 (33%)
61–90 76 (54%) 81 (57%)
Median (IQR) 62 (42–77) 63 (48–78)
Range 9–90 12–90 
History of superfi cial bladder cancer
No 110 (78%) 109 (76%)
Yes 29 (21%) 32 (22%)
Missing 2 (1%) 2 (1%)
pT category
pT1 4 (3%) 4 (3%)
pT2 28 (20%) 27 (19%)
pT3 86 (61%) 87 (61%)
pT4a 23 (16%) 24 (17%)
pT4b 0 1 (<1%)
pN category
pN0 42 (30%) 44 (31%)
pN1 50 (35%) 55 (38%) 
pN2 45 (32%) 44 (31%) 
pN3 4 (3%) 0 
pTN category 
pT1T2 N+ 32 (23%) 31 (22%) 
pT3T4 N– 42 (30%) 44 (31%) 
pT3T4 N+ 67 (48%) 68 (48%) 
pN by number of dissected nodes
pN– based on <15 dissected nodes 25 (18%) 27 (19%) 
pN– based on ≥15 dissected nodes 17 (12%) 17 (12%) 
pN+ based on <15 dissected nodes 60 (43%) 66 (46%) 
pN+ based on ≥15 dissected nodes 39 (28%) 33 (23%)
Highest G grade
G2 8 (6%) 14 (10%) 
G3 130 (92%) 125 (87%) 
Missing 3 (2%) 4 (3%)
Data are number (%), median (IQR), or range. 
Table 1: Baseline characteristics
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chemotherapy group vs 5·2 years [5·2–8·5] in the 
deferred chemotherapy group).
Patient characteristics were well balanced in the two 
treatment groups (table 1). The median age was 61 years 
(range 35–82), 226 (80%) of 284 patients were male, 
173 (61%) were pT3, 48 (17%) were pT4, and 198 (70%) 
were pN+. The median time from cystectomy to 
randomisation was 63 days (range 9–90).
At baseline, seven (2%) of 284 patients (three [2%] of 
141 patients in the immediate chemotherapy group vs 
four [3%] of 143 patients in the deferred chemotherapy 
group) had an incorrect disease stage or second primary 
cancer, another nine (3%) of 284 patients (four [3%] vs fi ve 
[3%]) had raised laboratory values or an auditory 
dysfunction and in eight (3%) of 284 patients (fi ve [4%] vs 
three [2%]) one or more of the eligibility criteria could not 
be verifi ed as a result of missing lab data. In total, 12 (9%) 
of 141 patients in the immediate chemotherapy group and 
12 (8%) of 143 patients in the deferred chemotherapy 
group had deviations from eligibility criteria. 
Patient disposition and compliance to allocated 
treatments are shown in fi gure 1 for all patients. 
Gemcitabine plus cisplatin was given to 165 (85%) of all 
195 treated patients. In the immediate treatment group, 
treatment was started in 128 (91%) of 141 patients, of 
whom 100 received four cycles and 28 received fewer 
than four cycles. Seven (5%) of the immediate treatment 
group refused treatment or were unfi t to receive it and no 
treatment information was available for six (4%) patients. 
Of the 143 patients in the deferred treatment group, three 
(2%) requested and received immediate chemotherapy 
and 64 (45%) started deferred chemotherapy at the time 
of progression, of whom 36 (56%) received six cycles, six 
(9%) fi ve cycles, eight (13%) four cycles, and 14 (22%) 
fewer than four cycles. 76 (53%) of 143 patients never 
started deferred treatment (53%), 53 (70%) of whom 
never progressed (fi gure 1; see appendix for treatment by 
pN status). 
Haematological, renal, and hepatic toxicities were 
consistent with those expected with cisplatin-based 
combination chemotherapy (table 2). In the 128 patients 
who received treatment in the immediate chemotherapy 
group, 76 (59%) had at least one cycle of treatment 
postponed for a maximum of 2 weeks because of 
adverse events, and the dose was reduced in 65 (51%). 
Immediate 
chemotherapy
(n=141)
Deferred 
chemotherapy
(n=143)
Survival status
Alive 75 (53%) 61 (43%) 
Dead 66 (47%) 82 (57%) 
Cause of death
Disease 52 (37%) 64 (45%) 
Toxicity 1 (<1%) 1 (<1%) 
Associated chronic disease 2 (1%) 0
Second primary 2 (1%) 3 (2%) 
Other 4 (3%) 8 (6%) 
Unknown 5 (4%) 6 (4%) 
Progression-free survival 
Alive without progression 68 (48%) 42 (29%) 
Progressed or died 73 (52%) 101 (71%) 
First progression event 
Distant metastasis 40 (28%) 53 (37%) 
Local or locoregional 23 (16%) 34 (24%) 
Progression, site unknown 1 (<1%) 1 (<1%) 
Died without progression 9 (6%) 13 (9%) 
Progression at any time during follow-up
 Any local or locoregional recurrence 41 (29%) 62 (43%) 
Any distant progression 47 (33%) 62 (43%) 
Any second primary or MDS 2 (1%) 10 (7%) 
Data are number (%). MDS=myelodysplastic syndrome.
Table 3: Clinical outcomes during follow-up
Immediate chemotherapy (n=128) Deferred chemotherapy (n=68)
Any grade Grade 1 Grade 2 Grade 3 Grade 4 Any Grade Grade 1 Grade 2 Grade 3 Grade 4
Haematological adverse events
Leucocytes 94 (73%) 19 (15%) 42 (33%) 29 (23%) 4 (3%) 54 (79%) 9 (13%) 21 (31%) 22 (32%) 2 (3%)
Neutrophils or granulocytes 80 (63%) 9 (7%) 22 (17%) 37 (29%) 12 (9%) 46 (68%) 3 (4%) 7 (10%) 22 (32%) 14 (21%)
Platelets 80 (63%) 21 (16%) 23 (18%) 23 (18%) 13 (10%) 45 (66%) 6 (9%) 13 (19%) 16 (24%) 10 (15%)
Haemoglobin 114 (89%) 53 (41%) 50 (39%) 10 (8%) 1 (<1%) 66 (97%) 18 (26%) 37 (54%) 9 (13%) 2 (3%)
Non-haematological adverse events
Bilirubin 10 (8%) 6 (5%) 2 (2%) 2 (2%) 0 10 (15%) 2 (3%) 5 (7%) 3 (4%) 0
Alkaline phosphatase 39 (30%) 33 (26%) 5 (4%) 1 (<1%) 0 34 (50%) 24 (35%) 7 (10%) 2 (3%) 1 (1%)
Alanine aminotransferase 42 (33%) 34 (27%) 7 (5%) 1 (<1%) 0 37 (54%) 26 (38%) 11 (16%) 0 0
Aspartate aminotransferase 19 (15%) 17 (13%) 2 (2%) 0 0 20 (29%) 15 (22%) 3 (4%) 2 (3%) 0
Serum creatinine 66 (52%) 55 (43%) 11 (9%) 0 0 41 (60%) 32 (47%) 9 (13%) 0 0
Data are number of patients with at least one event (% of patients). Adverse events were scored by Common Terminology Criteria for Adverse Events version 2.0. 
Table 2: Haematological, renal, and hepatic adverse events
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In the 67 patients who received treatment in the 
deferred chemotherapy group, 47 (70%) had treatment 
postponed and 52 (78%) had a dose reduction. 
21 patients stopped treatment because of toxicity: 
14 (11%) of 128 patients assigned to immediate 
treatment and seven (10%) of 67 patients assigned to 
deferred treatment.
As of the data cutoff  date of Aug 21, 2013, 148 (52%) of 
284 patients had died, 66 (47%) of 141 in the immediate 
treatment group and 82 (57%) of 143 in the deferred 
treatment group (table 3). 116 (41%) of 284 patients died 
due to their disease, 52 (37%) of 141 in the immediate 
treatment group and 64 (45%) of 143 in the deferred 
treatment group. Two patients were reported to have died 
due to treatment toxicity: one in the immediate treatment 
group died of neutropenic sepsis, the other died at home 
2 weeks after completing deferred treatment (the cause 
of death was unexplained).
5-year overall survival was 53·6% (95% CI 44·5–61·8) 
in the immediate treatment group and 47·7% (39·1–55·8) 
in the deferred treatment group, with corresponding 
median overall survival of 6·74 years (95% CI 3·85–not 
reached) and 4·60 years (2·15–6·25), respectively (HR 
0·78, adjusted 95% CI 0·56–1·08; p=0·13; fi gure 2A). For 
the entire population, 5-year overall survival was 50·5% 
(95% CI 44·3–56·4) with median overall survival of 
5·4 years (95% CI 3·7–6·9). At 5 years, bladder cancer 
mortality was 38·6% (95% CI 30·1–47·1) with immediate 
chemotherapy and 43·5% (35·2–51·8) with deferred 
chemotherapy, with competing risk-adjusted HR of 0·80 
(95% CI 0·56–1·15; p=0·22). We noted no diff erence in 
mortality due to other or unknown causes (competing 
risk HR 0·84, 95% CI 0·42–1·67, p=0·61; appendix).
As of the data cutoff , 174 (61%) of 284 patients had 
progressed or died (table 3). 64 (45%) patients in the 
immediate treatment group progressed, as did 88 (62%) 
in the deferred treatment group (table 3). Distant spread 
was present at the fi rst diagnosis of progression in 40 
(28%) of 141 patients in the immediate treatment group 
and 53 (37%) of 143 patients in the deferred treatment 
group (table 3). 5-year progression-free survival was 
47·6% (95% CI 38·8–55·9) in the immediate treatment 
group and 31·8% (24·2–39·6) in the deferred treatment 
group. Median progression-free survival was 3·11 years 
(95% CI 1·84–7·77) in the immediate treatment group 
compared with 0·99 years (0·63–1·49) in the deferred 
treatment group (HR 0·54, 95% CI 0·40–0·73; p<0·0001; 
fi gure 2B).
The duration of survival after progression was longer 
in the deferred treatment group than in the immediate 
treatment group (HR 1·45, 95% CI 1·02–2·07; p=0·037). 
In particular, patients with local or locoregional 
progression in the deferred group had a median survival 
of 2·31 years (95% CI 0·94–5·14) after starting treatment 
versus 1·11 years (95% CI 0·51–1·49) after starting 
treatment in those with local or locoregional progression 
in the immediate treatment group. 
We did post-hoc exploratory analyses to establish 
whether the size of the treatment eff ect varied according 
to a patient’s age at baseline, sex, pT category, pN 
category, or pTN category at baseline, and time from 
cystectomy to randomisation. For overall survival, we 
noted a signifi cant interaction only for the pN category 
(pN– vs pN+; pinteraction=0·026; fi gure 3A), whereas for 
progression-free survival, we noted no signifi cant 
interactions (fi gure 3B). Although overall survival results 
by extent of lymph node sampling also seemed to be 
signifi cant (pinteraction=0·028), interpretation is restricted by 
the small number of patients in this subcategory 
(fi gure 3A).
In patients without lymph node involvement at 
baseline, 5-year overall survival was 79·5% 
Figure 2: Kaplan-Meier survival curves 
(A) Overall survival. (B) Progression-free survival. HR=hazard ratio.
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(95% CI 63·0–89·2) in the immediate treatment group 
and 59·0% (42·6–72·2) in the deferred treatment group 
(HR 0·37, 95% CI 0·16–0·83; p=0·012; fi gure 4A), 
whereas in patients with lymph node involvement, 
5-year overall survival was 42·7% (32·3–52·8) in the 
immediate treatment group and 42·9% (32·9–52·6) in 
Figure 3: Subgroup analyses of survival and tests for interaction
(A) Overall survival. (B) Progression-free survival. HR=hazard ratio. *Data missing for four patients. †Unadjusted treatment eff ect. 
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the deferred treatment group (HR 0·94, 0·65–1·34; 
p=0·72; fi gure 4B). 
To further compare our results with those of the two 
most recent trials with similar design, we did a 
combined analysis of our primary results on overall 
survival with those reported by the Italian10 and Spanish11 
Cooperative Groups and with updated results of the 
other studies of combination or single-agent cisplatin in 
advanced urothelial carcinoma obtained from the 
analysis by Leow and colleagues.12 We noted an overall 
benefi t for adjuvant chemotherapy over the deferred 
chemotherapy group (HR 0·77, 95% CI 0·65–0·91; 
p=0·002; fi gure 5) with an I² value of 44·8%, suggesting 
heterogeneity. In particular, when restricting to the 
Italian, Spanish, and EORTC studies that mostly used 
gemcitabine plus cisplatin, severe heterogeneity was 
noted between the study results (I²=83·7%, hetero-
geneity p=0·002) and a borderline signifi cant benefi t of 
immediate gemcitabine plus cisplatin chemotherapy 
was noted (HR for overall survival 0·79, 95% CI 
0·62–1·00; p=0·05).
Discussion
This study is, to our knowledge, the largest randomised 
trial ever reported of adjuvant chemotherapy in patients 
with muscle-invasive bladder cancer. When compared 
with deferred chemotherapy, immediate adjuvant 
cisplatin-based combination chemotherapy after radical 
cystectomy did not lead to an improvement in overall 
survival, the primary endpoint, but was associated with 
signifi cantly longer progression-free survival. Exploratory 
analyses suggest that immediate chemotherapy might 
lengthen survival in patients without lymph-node 
involvement, but not in those who are node positive.
Randomised trials of adjuvant chemotherapy in muscle-
invasive bladder cancer have been laden with diffi  culties. 
All trials, including ours, have had problems in accrual, 
and most were stopped early without reaching their initial 
goal. Apart from early termination, earlier randomised 
trials had several limitations, including diff ering 
defi nitions of progression-free survival across trials, and 
they did not off er chemotherapy at the time of progression. 
Another issue is that the time at which patients were 
randomly assigned treatment also diff ered between the 
trials.26 These issues might have led to minor diff erences 
in the length of progression-free survival between trials.
In the present study, 198 (70%) of the 284 patients had 
regional lymph node involvement at baseline and 
because 52 (60%) of the 86 patients without lymph node 
involvement had fewer than 15 lymph nodes dissected, 
the proportion might be even higher. This group seems 
to be at very high risk, possibly diff ering from other 
recent adjuvant studies that had a much lower 
proportion of patients who were lymph-node positive. 
We found no signifi cant diff erence in overall survival 
with immediate chemotherapy compared with deferred 
treatment. Although the small numbers of patients make 
it diffi  cult to draw defi nitive conclusions, patients 
without lymph node involvement might have a survival 
benefi t from immediate post-cystectomy chemotherapy, 
but this result needs external validation in further 
randomised trials, especially since 52 (60%) of the 
86 patients who were node negative and 126 (64%) of the 
198 patients who were node positive were classifi ed on 
the basis of fewer than 15 dissected lymph nodes. 
For progression-free survival, a signifi cant diff erence 
in favour of immediate cisplatin-based chemotherapy 
therapy was reported, although this outcome was not the 
primary endpoint of the trial. Distant spread was present 
at the fi rst diagnosis of progression in 40 (28%) of 
Figure 4: Kaplan-Meier overall survival curves in patients who were node negative at baseline
Overall survival in patients who had no lymph node involvement at baseline (A) and those with lymph node 
involvement at baseline (B). HR=hazard ratio.
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141 patients in the immediate treatment group and 
53 (37%) of 143 patients in the deferred treatment group. 
The reason why the large diff erence in progression-free 
survival did not translate into a diff erence in overall 
survival might be related to the greater number of 
options for salvage that are available for patients who 
progress without having received chemotherapy, or it 
might be due to chance alone.
Diff ering from other trials, all centres in this trial chose 
an initial chemotherapy regimen to be used as immediate 
therapy, and were supposed to use the same regimen in 
the deferred treatment group at relapse. We did not 
intend to compare the diff erent chemotherapies because 
they were all regarded as having similar effi  cacy, and we 
were assessing whether or not immediate chemotherapy 
would be better than therapy at relapse. Furthermore, 
only 30 (15%) of the 195 patients who received treatment 
in our study received a regimen other than gemcitabine 
plus cisplatin.
One of the disadvantages associated with adjuvant 
chemotherapy over neoadjuvant chemotherapy is that 
complications after radical cystectomy can delay adjuvant 
chemotherapy or result in failure to receive treatment 
altogether. This study does not address this problem 
because patients were fi t to enter into the study and 
receive cisplatin-based chemotherapy. 
Neoadjuvant chemotherapy has also been assessed in 
patients with potentially micrometastatic disease. The 
major disadvantage of neoadjuvant chemotherapy is the 
diffi  culty with response assessment in the primary 
tumour before cystectomy, because clinical rather than 
pathological criteria are used.27 Additionally, delays to 
potentially curative surgery are risky if micrometastatic 
disease is not sensitive to systemic chemotherapy. Two 
randomised trials with cisplatin-based chemotherapy 
have shown a survival advantage with neoadjuvant 
chemotherapy compared with surgery alone or with 
defi nitive radiation therapy to the bladder.28,29 A meta-
analysis of neoadjuvant chemotherapy trials was done in 
2005 and suggests a survival benefi t with preoperative 
chemotherapy for muscle-invasive bladder cancer.27 
Nonetheless, neoadjuvant chemotherapy has been 
underused and physicians have in many cases preferred 
adjuvant chemotherapy despite the absence of good 
quality evidence to support its use. Patients are usually 
fi tter before cystectomy than afterwards, which would 
favour neoadjuvant chemotherapy, but physicians are 
concerned that this approach will cause delays before 
Figure 5: Updated scientifi c literature-based meta-analysis of studies of adjuvant chemotherapy for advanced urothelial carcinoma
O=observed. E=expected. HR=hazard ratio.
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cystectomy.30 This trend might, however, be reversing in 
the USA.31 
The current study will add further fuel to the debate. 
Although our trial was ultimately powered to detect an 
increase in 5-year overall survival from 50% to 65% 
(HR 0·62), the trial, like its predecessors, would clearly be 
underpowered to detect a survival diff erence of the 
magnitude reported in the 2005 individual patient data 
meta-analysis9 for adjuvant cisplatin-based combination 
chemotherapy studies (HR 0·75). Our results nonetheless 
suggest that adjuvant cisplatin-based chemotherapy can 
benefi t at least some subgroups of patients who have not 
undergone neoadjuvant chemotherapy. The previous 2005 
individual patient data meta-analysis of adjuvant 
chemotherapy9 should be updated to include our study 
and the Italian and Spanish studies10,11 to better analyse the 
role of adjuvant chemotherapy, something that the 
scientifi c literature-based meta-analysis cannot reliably 
do.12,32 When we combined the results of our study with 
the published results of the two most recent trials10,11 and 
updated results of the older studies,8,21–25 the results suggest 
a benefi t of immediate treatment on overall survival 
(HR 0·77, 95% CI 0·65–0·91; p=0·002; panel). However, 
there was substantial heterogeneity in the study results. 
Of note, a large international retrospective cohort of 
3947 patients from 11 centres, treated for urothelial 
carcinoma of any stage between 1979 and 2008, showed 
that adjuvant chemotherapy was independently 
associated with improved survival, particularly in patients 
at highest risk for disease progression; however, only half 
of the cohort were at an advanced stage.33
The present trial was initiated in 1999, when 
awareness and sensitivity to patient-reported outcomes 
was less. We regret not obtaining this data, because it 
would have potentially provided important information 
about the relevance of the observed eff ects. Another 
limitation of our study is that we did not obtain detailed 
information about salvage treatments and response to 
the salvage treatments. That information could have 
explained why the observed diff erence in progression-
free survival does not translate into a diff erence in 
overall survival. Central mandatory collection of samples 
and tumour banking were also less common when the 
study began. Similar to other adjuvant studies, tissue 
was not collected for translational research. Future trials 
should contain quality-of-life assessments and 
prospective sample collection, and hopefully biomarker 
research will enable us to better select patients who will 
benefi t from therapy. 
In conclusion, this trial, like its predecessors assessing 
adjuvant chemotherapy after radical cystectomy for 
advanced urothelial carcinoma, is limited in sample size 
and power for assessing its primary endpoint, overall 
survival. The results showed, however, a signifi cant 
increase in progression-free survival. Taken together 
with other similar studies, the results suggest that 
adjuvant chemotherapy might increase survival, at least 
in some subgroups of patients that this study alone 
cannot identify. An updated individual patient data meta-
analysis and biomarker research are needed to further 
elucidate the survival benefi t and its possible relation to 
pN status or other patient and disease factors. 
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Systematic review
Results of a 2005 individual patient-based meta-analysis comparing immediate adjuvant 
chemotherapy to no or delayed adjuvant chemotherapy suggested a decrease in the 
relative risk of death with adjuvant cisplatin-based chemotherapy (hazard ratio [HR] 
0·75), which represents a 9% (95% CI 1–16) absolute improvement in 3-year survival 
(p=0·02). The CIs were very wide since the survival analysis was based on only 
491 patients and 283 deaths.9 Because of the limited power of the meta-analysis and the 
methodological problems encountered in the studies included, the investigators 
concluded that evidence on which to reliably base treatment decisions concerning 
adjuvant chemotherapy in bladder cancer was insuffi  cient. Leow and colleagues’ 
literature-based meta-analysis12 of adjuvant chemotherapy trials included 945 patients 
from nine randomised controlled trials. This meta-analysis was based on summary 
statistics, such as the HR, that were obtained for each study either from the Cochrane 
Collaboration in 2005 or the study investigators, or were calculated from data extracted 
from the study publication. The results suggest an overall survival and disease-free 
survival benefi t with adjuvant cisplatin-based chemotherapy after radical cystectomy, but 
included a trial in patients with T1–T2 disease. 
Interpretation
Our intergroup international trial is, to our knowledge, the largest randomised trial 
reported of adjuvant chemotherapy in patients with muscle-invasive bladder cancer. 
Although immediate chemotherapy after radical cystectomy led to a signifi cant 
improvement in progression-free survival, overall survival was not improved. However, 
immediate chemotherapy might extend survival in patients without lymph-node 
involvement. When we combined our results with those of the two recent adjuvant 
chemotherapy trials of gemcitabine plus cisplatin and with the trials included in Leow and 
colleagues’ meta-analysis,12 we noted a benefi t of immediate treatment on overall 
survival (HR 0·77, 95% CI 0·65–0·91; p=0·002), although there was substantial 
heterogeneity. A new individual patient data meta-analysis of the available adjuvant 
chemotherapy trials is warranted. In patients with high-risk (T3–T4) bladder carcinomas 
who are candidates for cisplatin-based combination chemotherapy, in the absence of 
high level evidence, adjuvant chemotherapy could be an appropriate therapeutic option.
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